Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System.

Hugo Jourdain Lea Hoisnard Emilie Sbidian Mahmoud Zureik

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)

Our study does not support any association between exposure to rituximab biosimilars versus originator and hospitalization for a hypersensitivity reaction, either at initiation, at switch, or over time.

Keyphrases

diffuse large b cell lymphoma
drug induced
hodgkin lymphoma
chronic lymphocytic leukemia
electronic health record
big data
machine learning
artificial intelligence
deep learning